

September 10, 2020



# ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 22nd Annual Investment Conference

## Company to showcase its novel Alzheimer's, Parkinson's and ALS programs

TORONTO and CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in H.C. Wainwright & Co., 22<sup>nd</sup> Annual Investment Conference being held virtually September 14-16 2020.

ProMIS' Executive Chairman, Eugene Williams, will provide an update on the Company with special focus on the opportunities to detect, treat and ultimately prevent Alzheimer's disease. Mr. Williams' webcast presentation is scheduled for Tuesday, September 15, 2020 at 1:00 pm ET. The webcast will be available live and approximately 24 hours following the live presentation through the following link [here](#) and on the Company's [website](#).

### About ProMIS Neurosciences

ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer's, ALS and Parkinson's disease, the DSE's are misfolded regions on otherwise normal proteins. In the infectious disease setting, these disease-specific epitopes represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19. These peptide antigens can also be used to create potential therapeutic antibodies to treat active infection, as well as serve as the basis for development of vaccines. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at [www.promisneurosciences.com](http://www.promisneurosciences.com), follow us on [Twitter](#) and [LinkedIn](#)

For media inquiries, please contact:

Shanti Skiffington

[shanti.skiffington@gmail.com](mailto:shanti.skiffington@gmail.com)

Tel. 617 921-0808

For Investor Relations please contact:  
Alpine Equity Advisors  
Nicholas Rigopoulos, President  
nick@alpineequityadv.com  
Tel. 617 901-0785

*The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*



Source: ProMIS Neurosciences Inc.